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osting by EAbstract Carotid intima-media thickness (C-IMT) measured noninvasively by ultrasonography is
widely used as a marker for increased risk of cardiovascular disease. Also hyperuricemia (HU) is a
well recognized risk factor for cardiovascular diseases. The study was designed to assess the relation
between hyperuricemia and carotid intima-media thickness C-IMT in patients with and without
hypertension (HTN).
This study included 126 patients divided into four groups: (1) Group A, included 59 hypertensive
patients with hyperuricemia. (2) Group B, included 29 hypertensive patients without hyperuricemia.
(3) Group C, included 17 patients with hyperuricemia and normal blood pressure without history of
hypertension. (4) Group D, included 21 control subjects.
We measured carotid intima-media thickness by B-mode ultrasound in the common carotid and
internal carotid artery. Routine echocardiography and uric acid level was assessed for all patients.
We found that C-IMT was signiﬁcantly higher in group A, B and C than group D; and it was
signiﬁcantly higher in group A than B. This means that C-IMT is signiﬁcantly higher in all hyper-
tensive groups than control group but it was signiﬁcantly higher in hypertensive hyperuricemia
(group A) than those hypertensives without hyperuricemia. We also observed a higher C-IMT in
hyperuricemic non hypertensive patients than control group this means that hyperuricemia per se
could be a risk factor for atherosclerosis.m (A.S. Elsayed).
ity. All rights reserved. Peer-
d University.
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20 A.S. Elsayed et al.Uric acid levels among the whole number of patients included in the study and among the groups
with hyperuricemia (group A and group C) were positively correlated with the intimal-media thick-
ness (IMT) while there were no correlations in the other two groups without hyperuricemia.
We found that left ventricular hypertrophy (LVH) was signiﬁcantly higher in hypertensive
patients (group A&B) than normotensives (group C&D) either with or without hyperuricemia
and this was evident in the hypertensive hyperuricemic patients (group A); but unexpectedly we
observed the presence of LVH in the hyperuricemic non hypertensive patients (group C) which
was signiﬁcantly higher than the control group (group D). This means that hyperuricemia is a risk
factor for development of LVH hypertrophy independently of hypertension.
Therefore, higher serum uric acid levels are associated with increased C-IMT and left ventricu-
lar hypertrophy in hypertensive and even non hypertensive patients. So, early screening for
hyperuricemia and lowering serum uric acid levels might be beneﬁcial in slowing progression of
atherogenesis.
ª 2010 King Saud University. All rights reserved.1. Introduction
It has been proven that the atherosclerotic changes in the car-
otid artery mirror general atherosclerosis (Baroncini et al.,
2008). Carotid ntima-media thickness (C-IMT) is increasingly
used in clinical trials as an important risk marker to investigate
normal aging and preclinical atherosclerosis (Touboul et al.,
2004). Several studies demonstrated that carotid IMT is signif-
icantly associated with risk for myocardial infarction, stroke,
death from coronary artery disease, or a combination of these
events (Stein et al., 2008; Culleton et al., 1999; Dawson et al.,
2001; Ebrahim et al., 1999).
Hyperuricemia may be an independent risk factor associ-
ated with cardiovascular events (Alderman et al., 1999; Bickel
et al., 2002; World Health Organization, 1999) and it is often
considered as a part of metabolic syndrome or just a marker
of other coronary risk factors such as hypertension, dyslipide-
mia, obesity or renal disease (Kanellis et al., 2003).
The possible contributory effect of hyperuricemia to carotid
intima-media thickness (C-IMT) as marker of atherosclerosis
in hypertensive as well as non hypertensive patients has not
been clariﬁed.
This study was designed to assess the relation between
hyperuricemia and carotid intima-media thickness C-IMT in
patients with and without hypertension (HTN).
2. Patients and methods
This study was carried out at Aljedani Hospital and Ibn Sina
National Medical College in the Kingdome of Saudi Arabia
from ﬁrst of March 2009 to 31 August 2009. It included
126 patients divided into four groups: (1) Group A, included
59 hypertensive patients with hyperuricemia. (2) Group B, in-
cluded 28 hypertensive patients without hyperuricemia. (3)
Group C, included 17 non hypertensive patients with hyper-
uricemia. (4) Group D, included 21 control subjects non
hypertensive with normal uric acid and they did not receive
any medicine for hyperuricemia or hypertension in their past
history. From the patient groups we excluded patient with
systolic blood pressure of 220 mm Hg or higher, acute coro-
nary syndrome, stroke, or presence of a major illness such
as cancer, liver disease, renal insufﬁciency and insulin-treated
diabetes.
For all patients written consent, thorough history taking
and clinical examination were done. Carotid intima-mediathickness was measured by B-mode ultrasound in the common
carotid and internal carotid artery from the thickest area along
the course using Prosound Alfa 7 Aloka ultrasound machine
with broad band linear probe having a frequency of 1–
15 MGz. And if there is signiﬁcant stenosis by colored Doppler
the velocity was taken in the stenosed area.
Routine echocardiography was done for all patients includ-
ing left ventricular wall septal and posterior wall thickness,
ejection fraction and fractional shortening. Uric acid level
was assessed for all patients.
All data were categorized numerically, means and standard
deviation; Pearson correlation and chi-square test were ana-
lyzed by using Excel Microsoft Ofﬁce 2003. Signiﬁcance was
considered when p value < 0.05.
3. Results
For the demographic and clinical data there were no signiﬁ-
cant differences between all groups regarding age, sex and
heart rate (Table 1).
C-IMT was signiﬁcantly higher in group A, B and C than
group D (1.0 ± 0.4 mm, 0.92 ± 0.28, 0.91 ± 0.17 and
0.70 ± 0.15, respectively); and it was signiﬁcantly higher in
group A than B. This means that C-IMT is signiﬁcantly higher
in all hypertensive groups than control group but within
hypertensive groups it was signiﬁcantly higher in those with
hyperuricemia (group A) than those hypertensives without
hyperuricemia (group B). Also among non hypertensive pa-
tients C-IMT was higher in hyperuricemic group C than con-
trol group D.
Uric acid levels among the whole number of patients in-
cluded in the study were positively correlated with C-IMT.
Also uric acid levels in the groups with hyperuricemia (group
A and group C) were positively correlated with C-IMT while
there were no correlations in the other two groups without
hyperuricemia (B and D) (see Figs. 1–5).
Left ventricular hypertrophy was signiﬁcantly higher in
hypertensive groups (A&B) than non hypertensive groups
(C&D), also It was signiﬁcantly higher in group A (hyperten-
sive hyperuricemic) than group B (hypertensive non hyperuri-
cemic). While among the non hypertensive groups (A&B) LVH
was higher signiﬁcantly in the hyperuricemic patients (group
C) than control group D without hyperuricemia: this observa-
tion means that hyperuricemia per se has a relation to LVH in
non hypertensive patients.
Figure 4 The correlation between serum uric acid level and C-
IMT in the normotensive hyperuricemic group of patients (group
C).
Figure 2 The correlation between serum uric acid level and C-
IMT in the hypertensive hyperuricemic group of patients (groupA).
Figure 3 The correlation between serum uric acid level and C-
IMT in the hypertensive patients with normal uric acid (group B).
Figure 1 The correlation between serum uric acid level and C-
IMT in the whole number of patients.
Figure 5 The correlation between serum uric acid level and C-
IMT in the control subjects (group D).
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The association between hyperuricemia and hypertension and
the pathogenesis of atherosclerosis is still unclear. The present
study was made in order to observe if hyperuricemia has a pos-
sible role in developing atherosclerosis in hypertensive and non
hypertensive subjects.
In our study the control subjects (group D) who have the
mean age of 40.5 ± 9.0; C-IMT was 0.70 ± 15 and this was
similar to the normal value found in other study by Lim
et al. (2008) who found that the normal value of the upper lim-
its of C-IMT at the common carotid artery for the age 35–39,
40–49, 50–59, and 60 years or older were 0.60, 0.64, 0.71, and
0.81 mm, respectively, whereas for that at its bifurcation were
0.83, 0.77, 0.85, and 1.05 mm, respectively.We observed that C-IMT is higher in patients with hyper-
tension, with or without hyperuricemia, compared with the
control group, while it was higher in hypertensive hyperurice-
mic than hypertensive non hyperuricemic patients. We also ob-
served a higher C-IMT in hyperuricemic non hypertensive
patients (group C) than control group (group D). This means
that hyperuricemia per se could be a risk factor for atheroscle-
rosis in both hypertensive as well as non hypertensive patients.
In consistent with our results Tavil et al. (2008) found that
C-IMT was signiﬁcantly higher in the hypertensive patients
with or without hyperuricemia compared to the control cases
(0.70 ± 0.14, 0.83 ± 0.16 versus 0.57 ± 0.16 mm, respec-
tively, p< 0.001).
We noticed that there were signiﬁcant correlations between
C-IMT and serum uric acid levels among the whole number of
subjects included in the study and this correlation was more
evident in the hypertensive hyperuricemic (group A) and also
in hyperuricemic normotensive (group C).
This result was similar in a study done by Savoiu et al.
(2008) in 2008, who studied the effect of hyperuricemia among
hypertensive patients but there study did not include the effect
of hyperuricemia in the normotensive subjects.
We observed also that left ventricular hypertrophy (LVH)
was signiﬁcantly higher in hypertensive patients (group
A&B) than normotensives (group C&D) either with or without
hyperuricemia and this was evident in the hypertensive hyper-
uricemic patients (group A); but unexpectedly we observed the
presence of LVH in the hyperuricemic non hypertensive pa-
Table 1 Clinical characteristics and biochemical parameters of the study subjects.
Group A with HTN
and HU (no 59 pts)
Group B with HTN
without HU (no 29 pts)
Group C normotensives
with HU (no 17 pts)
Group D control
group (no 21 pts)
Age (years) 51.98 ± 8.89 53.06 ± 9.06 64.7 ± 11 40.52 ± 9.03
Male (%) 76.3 85.7 75 76.1
Diabetes mellitus (%) 45.7 58.6 11.7 0
Left ventricular hypertrophy (%) 57.6 51.7 41.1 0
HDL–cholesterol (mg/dl) 43.5 ± 9.5 42.0 ± 9.4 42 ± 7.6 48.9 ± 7.1
LDL–cholesterol (mg/dl) 143.7 ± 36.1 132.6 ± 47.8 134.6 ± 28.1 104.7 ± 20.1
Triglycerides (mg/dl) 189.6 ± 88.8 179.5 ± 54.9 214.3 ± 100.1 142.9 ± 49.8
Systolic blood pressure (mm Hg) 161.0 ± 17.1 160.5 ± 18.3 125.6 ± 11.8 126.4 ± 9.9
Diastolic blood (mm Hg) 95.7 ± 8.6 93.3 ± 9.09 80.9 ± 5.7 79.04 ± 6.8
Uric acid (lmol/l) 478.7 ± 94.5 326.7 ± 50.8 461.4 ± 91.1 327.3 ± 62.6
Carotid IMT (mm) 1.0 ± 0.40 0.92 ± 0.28 0.91 ± 0.17 0.70 ± 0.15
22 A.S. Elsayed et al.tients (group C) which was signiﬁcantly higher than the control
group (group D). This means that hyperuricemia is a risk fac-
tor for development of LVH hypertrophy independently of
hypertension.
However, many studies found the relation between LVH
and high uric acid in hypertensive patients but scars reports
studied this relation in those without hypertension.
In consistent with our study Mitsuhashi et al. (2009) found
that hyperuricemia positively and independently associated left
ventricular hypertrophy in Japanese non hypertensive men. In
there study they as assessed LVH depending on electrocardio-
graphic (ECG) criteria while in our study we assessed LVH by
echocardiographic measurements of left ventricular posterior
wall.
Kurata et al. (2005) reported that serum uric acid levels cor-
related positively with left ventricular mass and indexed left
ventricular mass in male hypertensive patients but not in fe-
male hypertensive patients. Iwashima et al. (2006) also demon-
strated an independent association between uric acid and left
ventricular mass index and they suggested that the combina-
tion of hyperuricemia and LVH is an independent and power-
ful predictor of cardiovascular disease.
Many studies explained the effect of uric acids on LVH and
endothelial dysfunction, it is reported to inhibit the generation
of nitric oxide, thus inducing endothelial dysfunction and
smooth muscle cell proliferation by activating inﬂammatory
mediators such as tumor necrosis factor-alpha and mitogen-
activated protein kinases (Iwashima et al., 2006; Khosla
et al., 2005). UA is also capable of activating the rennin–angio-
tensin system, which is thought to mediate the development of
LVH through many mechanisms (Agabiti-Rosei et al., 2006;
Nakahara et al., 2007).
5. Conclusion
Carotid intimal media thickness C-IMT is increased in patients
with hypertension as well as in patients with hyperuricemia
without hypertension compared to the control group but it
was more evident in hypertensive hyperuricemic patients.
Left ventricular hypertrophy is signiﬁcantly higher in
hyperuricemic patients than those without hyperuricemia espe-
cially in hypertensives as well as non hypertensives.
These results suggest that higher serum uric acid levels are
associated with atherogenesis and left ventricular hypertrophy.
Therefore, early screening for hyperuricemia and lowering ser-um uric acid levels might be beneﬁcial in slowing progression
of atherosclerosis in hypertensive and non hypertensive
patients.
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